CORRECTED: FTC Pulls Antitrust Probe Over Yasmin Deals

Law360, New York (October 2, 2012, 12:00 AM EDT) -- Settlements between Bayer Schering Pharma AG and Barr Laboratories Inc. relating to patent infringement allegations over Bayer's Yasmin birth control drug will no longer be subject to antitrust scrutiny, as the Federal Trade Commission said on Monday that it is closing an investigation into the deals' potential competitive harms.

In a pair of letters to Barr — which has in recent years been acquired by Teva Pharmaceutical Industries Ltd. — and Bayer, the FTC said that it is closing its probe into whether deals over patent...
To view the full article, register now.